You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,602,006


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,602,006
Title: Heteropolymeric protein production methods
Abstract:Cultured mammalian cell transfected with new vectors comprising full-length or partial .alpha. and .beta. subunit genomic DNA sequences produce significantly higher levels of dimeric glycoprotein hormone than do cells transfected with .alpha. and .beta. subunit cDNA sequences. In cases where only the cDNA clones are available, the cDNA sequences can be used in new expression vectors comprising introns or other important genomic regions from a homologous or heterologous source.
Inventor(s): Kelton; Christie A. (Hopkinton, MA), Nugent; Noreen P. (Framingham, MA), Chappel; Scott C. (Boston, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:08/455,396
Patent Claims:1. A method for increasing the production of a protein in a host cell transformed with a vector comprising DNA encoding for said protein, wherein said protein is the .alpha.-subunit of a dimeric protein selected from the group consisting of luteinizing hormone, follicle stimulating hormone, chorionic gonadotropin and thyroid stimulating hormone, comprising:

(a) providing a vector comprising a promoter, a structural gene encoding said .alpha.-subunit of said dimeric protein and a terminating sequence, said promoter, structural gene and terminating sequence being operatively linked to permit expression of said gene when a host cell is appropriately transformed by said vector, wherein said structural gene comprises a coding region and at least one intron, wherein one intron is immediately 5' to the coding region of the .alpha.-subunit, with the proviso that said structural gene is not the entire genomic sequence of the gene encoding said .alpha.-subunit;

(b) transforming host cells with said vector; and

(c) culturing said transformed cells under conditions by which the .alpha.-subunit protein is produced,

whereby an amount of .alpha.-subunit protein is produced which is greater than that which can be produced under comparable conditions using a structural gene encoding the .alpha.-subunit which is the cDNA without introns.

2. A method in accordance with claim 1, wherein said structural gene comprises DNA encoding the amino acid sequence Met Asp Tyr Tyr Arg Lys Tyr Ala Ala Ile Phe Leu Val Thr Leu Ser Val Phe Leu His Val Leu His Ser Ala Pro Asp Val Gln Asp Cys Pro Glu Cys Thr Leu Gln Glu Ash Pro Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu Val Gln Lys Asn Val Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser Tyr Asn Arg Val Thr Val Met Gly Gly Phe Lys Val Glu Asn His Thr Ala Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser.

3. A method in accordance with claim 1, wherein said structural gene contains only a single intron.

4. A method in accordance with claim 1, wherein said structural gene is produced by adding, by recombinant DNA techniques, said at least one intron to the cDNA encoding said .alpha.-subunit.

5. A method in accordance with claim 1, wherein said one intron which is immediately 5' to the coding region of the .alpha.-subunit naturally occurs in the genomic sequence of the gene encoding the .alpha.-subunit of the natural dimeric protein corresponding to the dimeric protein the .alpha.-subunit of which is being produced.

6. A method in accordance with claim 5, wherein said structural gene comprises Met Asp Tyr Tyr Arg Lys Tyr Ala Ala Ile Phe Leu Val Thr Leu Ser Val Phe Leu His Val Leu His Ser Ala Pro Asp Val Gln Asp Cys Pro Glu Cys Thr Leu Gln Glu Asn Pro Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu Val Gln Lys Asn Val Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser Tyr Asn Arg Val Thr Val Met Gly Gly Phe Lys Val Glu Asn His Thr Ala Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser.

7. A method in accordance with claim 5, wherein said structural gene contains only a single intron.

8. A method in accordance with claim 5, wherein said structural gene is produced by adding, by recombinant DNA techniques, said at least one intron to the cDNA encoding said .alpha.-subunit.

Details for Patent 5,602,006

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 01/15/1974 ⤷  Try a Trial 2014-02-11
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 12/27/1984 ⤷  Try a Trial 2014-02-11
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/15/1985 ⤷  Try a Trial 2014-02-11
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/16/1990 ⤷  Try a Trial 2014-02-11
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 03/26/1974 ⤷  Try a Trial 2014-02-11
Fresenius Kabi Usa, Llc CHORIONIC GONADOTROPIN chorionic gonadotropin For Injection 017067 03/05/1973 ⤷  Try a Trial 2014-02-11
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2014-02-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.